论文部分内容阅读
Immunotherapy has the potential to improve clinical outcomes with little toxicity for pediatric patients with brain tumors.We conducted a pilot feasibility study of tumor lysate-pulsed dendritic cell(DC)vaccination in pediatric patients(1 to 18 years old)with newly diagnosed or recurrent high-grade glioma(HGG).A total of nine DC vaccine doses,each containing 1×10(6)cells per dose were administered to three out of the seven originally enrolled patients.Toxicities were limited to mild side-effects,except in one case
Immunotherapy has the potential to improve clinical outcomes with little toxicity for pediatric patients with brain tumors. We conducted a pilot feasibility study of tumor lysate-pulsed dendritic cell (DC) vaccination in pediatric patients (1 to 18 years old) with newly diagnosed or recurrent High-grade glioma (HGG). A total of nine DC vaccine doses, each containing 1 × 10 (6) cells per dose were administered to three out of the seven originally enrolled patients. Toxicities were limited to mild side-effects, except in one case